Abstract: The invention provides compounds of formula (I): and salts thereof, wherein X and Y have any of the values defined herein. The compounds inhibit bacterial RNA polymerase, inhibit bacterial growth, and have applications in, analysis of RNA polymerase structure and function, control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, antibacterial therapy, and drug discovery.

Abstract: The present invention relates to methods of generating highly concentrated protein solutions, e.g., an antibody solution, a therapeutic protein solution, etc. The methods of the invention include membrane evaporation, such as evaporation of protein-free solvent from the protein solution, which concentrates the protein. The methods of the present invention result in protein solution concentrations not previously achievable by conventional ultrafiltration methods, e.g., protein solution concentrations of greater than about 260 grams of protein per liter of solution.

Abstract: A method is provided for treatment of a condition mediated by Nox2 in a patient. The method comprises administering to the patient by inhalation a polypeptide as described herein, able to inhibit superoxide production by Nox2. Conditions treatable in this manner include, without limitation, one or more of: right ventricular hypertrophy; pulmonary hypertension; acute lung injury; obstructive sleep apnea; ischemia/reperfusion injury in the lung; pulmonary fibrosis; an obstructive lung disorder such as Chronic Obstructive Pulmonary Disease (COPD), asthma, cystic fibrosis and emphysema; and atherosclerosis.

Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.

Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Abstract: Provided is a peptide selectively binding to a volatile organic compound, in which the peptide has excellent selectivity for the volatile organic compound and has stability at room temperature so as to effectively collect and detect or eliminate the volatile organic compound.

Abstract: Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations. The compounds described herein include conjugates of tubulysins and vitamin receptor binding ligands. The conjugates also include a releasable bivalent linker.

Abstract: The present disclosure provides antimicrobial peptides, and compositions comprising same. The present disclosure further provides methods of inhibiting microbial growth.

Abstract: The present invention provides a polypeptide able to specifically bind to rare-earth nanoparticles and the use thereof. The polypeptide comprises an amino acid sequence shown by SEQ ID NO: 1 or analogs thereof. The present invention further provides a method for screening a polypeptide having the capacity of specifically binding to rare-earth nanoparticles. The present invention further provides a method for regulating and controlling the in vivo and in vitro autophagy and toxicity of the rare-earth upconversionnanophosphor material, comprising mixing and incubating the polypeptide specifically binding to rare-earth nanoparticles with rare-earth upconversion nanophosphor material, such that the polypeptide specifically binds to the nanophosphor material, wherein the rare-earth upconversion nanophosphor material comprises the rare earth, and the polypeptide specifically binding to rare-earth nanoparticles comprises the amino acid sequence shown by CTARSPWIC (RE-0, SEQ ID NO: 1) or analogs thereof.

Abstract: The present disclosure relates to crystalline form of (S)—N—((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (S)—N—((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same.

Abstract: Human phoenixin peptides, analogs and mimetics useful in production of anti-phoenixin antibodies, diagnostic screening and assays, and in modulating cellular concentration of cAMP, and treatment of disorders related to cAMP or Ca2+ concentration in cells, modulating hypertension and cardiovascular function, modulating gonadotrophs and gastric emptying.

Abstract: Administration of compositions comprising cell-permeable cancer-specific proliferating cell nuclear antigen derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins.

Abstract: The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

Abstract: A method for enhancing skin collagen in an individual includes administering a composition to the individual, the composition comprising a skin collagen enhancing agent comprising menaquinone-7 as an active ingredient. In addition, a composition is provided in the form of at least one of an emulsion and a cream, the composition including a skin collagen enhancing agent comprising menaquinone-7 as an active ingredient.

Abstract: The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

Abstract: The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.

Abstract: An active mixture having (a) acylated oligopeptides, and (b) troxerutin, useful for increasing hair growth and in particular density of eyelashes and eyebrows.

Abstract: A single-chain insulin analog containing a basic side chain at position A8 (Arginine, Histidine, Lysine, or Ornithine), a basic side chain at position B29 (Arginine, Histidine, Lysine, or Ornithine), and a foreshortened C-domain of length 6-11 residues is provided. Residues C1 and C2 of the C-domain have a net negative charge of ?1 or ?2; C3 is chosen from a group consisting of Gly, Ala, Pro, or Ser; and the remaining C-domain segment is successively derived from the C-domain of IGF-II (RRSR (SEQ ID NO: 18), SRRSR (SEQ ID NO: 17), VSRRSR (SEQ ID NO: 16), RVSRRSR (SEQ ID NO: 15), or SRVSRRSR SEQ ID NO: 13). A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to a patient.

Abstract: There is provided pharmaceutical compositions suitable for the treatment of infected ulcers in mammals, such as diabetes related ulcers and varicose ulcers. Said compositions comprise vancomycin, gentamicin, amikacin, fluconazole, ciprofloxacin and metronidazole or its corresponding salts and an hypertonic amount of sodium chloride in a suitable polar and aprotic or protic acidic as pharmaceutical carrier. There is further disclosed a methods for treating ulcers in mammals using the disclosed compositions.

Abstract: A composition in aqueous solution, including an insulin and at least one oligosaccharide whose average degree of polymerization is between 3 and 13 and whose polydispersity index PDI is above 1.0, the oligosaccharide having partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable.